Feedback / Questions
EPIAO (recombinant human erythropoietin biosimilar) - 3SBio
3SBio: Interim Results 2016 Investor Conference Call
(3SBio)
-
Aug 28, 2016 -
Anticipated completion of multi-center biosimilar clinical trials (NCT02522975) in Russia and Thailand by 2017
Anticipated trial completion date
•
Biosimilar
http://www.3sbio.com/images/stories/PDF/3SBio_2016_Interim_Results_Company_Presentation_Material_EN_Final.pdf
Aug 28, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious